Top Markets
#1 ADO Protocol ADO Protocol +336.33%
#2 Islamic Coin Islamic Coin +155.40%
#3 GoPlus Security GoPlus Security +51.61%
#4 Starpower Starpower +33.70%
#5 GAIB AID GAIB AID +24.67%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.27%
#7 The Black Bull The Black Bull +15.49%
#8 Nockchain Nockchain +14.55%
#9 XMAQUINA XMAQUINA +12.20%
#10 Casper Network Casper Network +11.65%
Coin of the day
ADO Protocol ADO Protocol
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Eagle Pharmaceuticals, Inc. Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

EGRX
Rang in Aktien #33346
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on... Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Aktienkurs
$0.595
Zuletzt synchronisiert: 2026-08-13
Marktkapitalisierung
$7.83M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-81.41%
Land
US
Handel Eagle Pharmaceuticals, Inc. (EGRX)

Kategorie

Healthcare
Gewinn für Eagle Pharmaceuticals, Inc. (EGRX)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Eagle Pharmaceuticals, Inc. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Eagle Pharmaceuticals, Inc. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
$1.76B -
IN